<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986348</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-004</org_study_id>
    <nct_id>NCT01986348</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas</brief_title>
  <acronym>KING</acronym>
  <official_title>A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral
      selinexor in patients with recurrent gliomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral
      selinexor in patients with recurrent gliomas.

      Initially, the study included 2 arms: an exploratory Surgical Arm (Arm A) with sequential
      enrollment for patients who require surgery and a medical arm (Arm B) for patients who are
      not eligible for surgery.

      Enrollment in Arm B was stopped to explore alternative dosing in Protocol Versions ≥ 4.0 to
      potentially improve tolerability. Four arms (Arms C, D, E, and F) were added to the Medical
      Arm in Protocol Version 4.0. Arms E and F were eliminated in protocol version 6.0 and no
      patients were ever enrolled in these arms.

      Patients in the primary population enrolled under Protocol Version ≥ 4.0 will be randomized
      to Arm C and Arm D (approximately 30 patients per arm) to explore alternative dosing to
      potentially improve tolerability.

      After screening and registration/randomization in the study, patients enrolling in Arm A or
      randomized to Arm C will receive 60 mg selinexor orally twice weekly. Patients randomized to
      Arm D will receive 80 mg selinexor orally weekly.

      Patients will be treated until progression of disease or the development of unacceptable
      toxicities. All patients will then undergo the End of Treatment (EOT) visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">January 23, 2020</completion_date>
  <primary_completion_date type="Actual">January 23, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with 6 months of progression-free survival (6mPFS) in Arms B, C, and D</measure>
    <time_frame>6 months</time_frame>
    <description>Progression will be determined by the Response Assessment in Neuro-Oncology (RANO) criteria</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Arm A: Selinexor and surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who require surgery will receive up to 3 doses of selinexor, undergo surgery, and resume selinexor after recovery. Selinexor will be given twice weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Selinexor only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were not eligible for surgery may be randomized to take selinexor twice weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Selinexor only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were not eligible for surgery may be randomized to take selinexor once weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>One cycle is 28 days (4 weeks).</description>
    <arm_group_label>Arm A: Selinexor and surgery</arm_group_label>
    <arm_group_label>Arm C: Selinexor only</arm_group_label>
    <arm_group_label>Arm D: Selinexor only</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed GBM (including all histologic variants) at first diagnosis
             with radiographic evidence of recurrent disease after treatment with radiotherapy and
             temozolomide;

          -  18 years of age or older

          -  Patients enrolling in the medical arm (Arms C and D) must be on a stable or decreasing
             dose of corticosteroids (or none) for at least 5 days prior to the baseline MRI;

          -  Measurable disease (according to RANO guidelines)

          -  Surgical arm (Arm A) must be predicted pre-operatively to have sufficiently sized
             tumor to be resected and provide tissue samples for exploratory assessments.

        Exclusion Criteria:

          -  Markedly decreased visual acuity if attributed to other causes than GBM.

          -  Known active hepatitis A, B, or C

          -  Patients with coagulation problems and medically significant bleeding in the month
             prior to start of treatment (e.g., peptic ulcer, epistaxis, spontaneous bleeding).
             Prior history of DVT or PE is not exclusionary.

          -  Patients must not have significantly diseased or obstructed gastrointestinal tract,
             malabsorption, uncontrolled vomiting or diarrhea, or inability to swallow oral
             medications.

          -  Prior treatment with bevacizumab or other direct VEGF/ VEGFR inhibitors. For any
             question of the definition of a direct VEGF/VEGFR inhibitor, consult Sponsor.

          -  Arms C and D only: body surface area &lt; 1.2 m².

          -  &lt; 24 days from prior temozolomide, &lt; 6 weeks from nitrosourea, &lt; 4 weeks from other
             chemotherapy or investigational agents prior to start of treatment within study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Mau-Sørensen, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Phase I Unit, Dept. of Oncology, Rigshospitalet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew B Lassman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute, Center for Neuro-Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University, Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Phase I Unit, Dept. of Oncology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Groningen Faculty of Medical Sciences, Medical Oncology</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC-Daniel den Hoed Cancer Center- Neuro-Oncology Unit</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GBM</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>selinexor</keyword>
  <keyword>KPT-330</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>brain tumor</keyword>
  <keyword>brain cancer</keyword>
  <keyword>Glioma</keyword>
  <keyword>Astrocytoma</keyword>
  <keyword>Oligodendrogliomas</keyword>
  <keyword>Oligo-astrocytomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

